Yale mouse study finds Ozempic may sustain weight loss by switching on, not silencing, the brain's hunger cells

Yale researchers report in PNAS that semaglutide, the active ingredient in Ozempic and Wegovy, appears to sustain fat loss in mice partly by activating, not silencing, the brain's hunger-promoting AgRP neurons. The finding, dated 10 August 2026, challenges a long-standing assumption about how GLP-1 receptor agonists work and points the field toward a new class of obesity drugs built around appetite-maintenance circuitry.

For two decades, the working model treated AgRP (agouti-related peptide) neurons as the villains of obesity research. These cells, clustered in the arcuate nucleus of the hypothalamus, are among the brain's most potent hunger drivers: activate them and mice eat; silence them and they eat less. GLP-1 drugs, by that logic, should quiet them. The Yale team, led by first author Mateus d'Ávila, a PhD candidate in Tamas Horvath's lab in the Department of Comparative Medicine at Yale School of Medicine, found the opposite. When they knocked out AgRP neurons in mice, semaglutide still blunted food intake, but the animals failed to keep the fat off. AgRP activity is not what GLP-1s suppress; it is part of how they preserve the lower weight.

Older anorectics such as phentermine suppress appetite nearly as well as GLP-1s do, but their weight loss fades as the body compensates. Semaglutide produces sustained body-weight reductions of 10-15% or more in clinical trials. Patients on either drug report comparable fullness at the trough. The durability gap sits in whether the brain re-weights its "set point" after weight loss, with AgRP recruitment as the lever.

The experiments were in female mice only, which limits direct translation to a human obesity drug. Earlier anorectics also act on AgRP biology without producing semaglutide's durability, which means the Yale team has shown AgRP recruitment is necessary for the effect, not that it is sufficient. Replication in male mice, in other species, and ultimately in humans is the next step.

The authors frame AgRP-recruitment biology as a candidate target for next-generation obesity drugs intended to be more effective or durable than semaglutide, rather than a vindication of current therapies. A drug that locks the brain's weight set point at a lower level would be a different commercial product than the weekly injections now sold, with a different conversation about when to start and stop treatment.

The finding entered the press cycle through a Yale News release, and was picked up the same week by ScienceDaily, SciTechDaily, and Medical Xpress. The PNAS paper is the primary record. The watch item is whether independent labs replicate the AgRP-recruitment finding in male mice and in higher species; the design lane only opens for real once the mechanism holds outside the original lab's female-mouse cohort.